GLPBio

VER 155008

Catalog No.: GC16966Purity:>99.50%Synonyms: adenosine-derived inhibitor, VER155008, VER-155008
VER 155008 is a potent, adenosine-derived inhibitor of the heat shock protein 70 (Hsp70) family, with IC50 values of 0.5μM, 2.6μM, and 2.6μM against Hsp70, heat shock cognate protein 70 (Hsc70), and glucose-regulated protein 78 (Grp78), respectively.

Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.


VER 155008
Cas No.: 1134156-31-2
10mM (in 1mL DMSO)In Stock
$57.00
1
1mgIn Stock
$19.00
1
5mgIn Stock
$46.00
1
10mgIn Stock
$60.00
1
50mgIn Stock
$208.00
1
100mgIn Stock
$360.00
1

Zitate (Citations)

Für dieses Produkt sind derzeit keine Zitate verfügbar. Nachfolgend finden Sie ausgewählte Publikationen, die GlpBio-Produkte zitieren.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Beschreibung (Description)

VER 155008 is a potent, adenosine-derived inhibitor of the heat shock protein 70 (Hsp70) family, with IC50 values of 0.5μM, 2.6μM, and 2.6μM against Hsp70, heat shock cognate protein 70 (Hsc70), and glucose-regulated protein 78 (Grp78), respectively[1]. VER 155008 exerts its effects by inhibiting Hsp70 ATPase activity, inducing cell cycle arrest, apoptosis, and tumor-specific cell death, and is commonly used in anti-cancer (e.g., prostate and breast cancer) and antiviral research[2,3,4].

In vitro, treatment with VER 155008 (20μM) for 48h in 211H and H28 cells significantly increased the proportion of cells in the G1 phase (from 69.9% to 82.7% in 211H cells; from 77% to 85.2% in H28 cells)[5]. VER 155008 (25μM) treatment in A549 and H1975 cells for 2 days significantly reduced the percentage of 5-bromo-2'-deoxyuridine (BrdU)-positive cells, indicating inhibition of cell proliferation[6].

In vivo, intraperitoneal injection of VER 155008 (40mg/kg; once daily) for two weeks in PC12 tumor-bearing nude mice significantly reduced tumor volume and tumor weight[7]. A single intravenous dose of VER 155008 (25mg/kg) in BALB/c mice resulted in a plasma half-life of 0.6h and a clearance rate of 49mL/min/kg[1].

References:
[1] MASSEY A J, WILLIAMSON D S, BROWNE H, et al. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells[J]. Cancer Chemotherapy and Pharmacology, 2010, 66(3): 535-545.
[2] BUDINA-KOLOMETS A, BALABURSKI G M, BONDAR A, et al. Comparison of the activity of three different HSP70 inhibitors on apoptosis, cell cycle arrest, autophagy inhibition, and HSP90 inhibition[J]. Cancer Biology & Therapy, 2014, 15(2): 194-199.
[3] WENG J R, HUA C H, CHEN C H, et al. Anti-apoptotic activity of Japanese encephalitis virus NS5 protein in human medulloblastoma cells treated with interferon-β[J]. Journal of Microbiology, Immunology and Infection, 2018, 51(4): 456-464.
[4] YU B, YANG H, ZHANG X, et al. Visualizing and quantifying the effect of the inhibition of HSP70 on breast cancer cells based on laser scanning microscopy[J]. Technology in Cancer Research & Treatment, 2018, 17: 1533033818785274.
[5] SAKAI K, INOUE M, MIKAMI S, et al. Functional inhibition of heat shock protein 70 by VER‐155008 suppresses pleural mesothelioma cell proliferation via an autophagy mechanism[J]. Thoracic Cancer, 2021, 12(4): 491-503.
[6] WEN W, LIU W, SHAO Y, et al. VER-155008, a small molecule inhibitor of HSP70 with potent anti-cancer activity on lung cancer cell lines[J]. Experimental Biology and Medicine, 2014, 239(5): 638-645.
[7] XU F, LIN D, JIANG W, et al. HSP70 inhibitor VER155008 suppresses pheochromocytoma cell and xenograft growth by inhibition of PI3K/AKT/mTOR and MEK/ERK pathways[J]. International Journal of Clinical and Experimental Pathology, 2019, 12(7): 2585.

Protokoll (Protocol)

Cell experiment [1]:

Cell lines

A549 and H1975 cells

Preparation Method

A549 and H1975 cells were treated with 25μM VER 155008 for 2 days, then incubated with 10μM BrdU for 1h. BrdU-positive cells were detected by anti-BrdU FITC antibody.

Reaction Conditions

25μM; 2 days

Applications

Treatment with VER 155008 significantly reduced the percentage of BrdU-positive cells and inhibited cell proliferation.
Animal experiment [2]:

Animal models

Nude mice xenografted with PC12 tumor cells

Preparation Method

PC12 cells (1×106 cells) were injected subcutaneously into nude mice. When tumors reached 80-150mm3, mice were intraperitoneally injected with VER 155008 (40mg/kg) once daily for 2 weeks. Tumor volume were measured every day.

Dosage form

40mg/kg; once daily; 2 weeks; i.p.

Applications

Treatment with VER 155008 significantly reduced tumor volume.

References:
[1] WEN W, LIU W, SHAO Y, et al. VER-155008, a small molecule inhibitor of HSP70 with potent anti-cancer activity on lung cancer cell lines[J]. Experimental Biology and Medicine, 2014, 239(5): 638-645.
[2] XU F, LIN D, JIANG W, et al. HSP70 inhibitor VER155008 suppresses pheochromocytoma cell and xenograft growth by inhibition of PI3K/AKT/mTOR and MEK/ERK pathways[J]. International Journal of Clinical and Experimental Pathology, 2019, 12(7): 2585.

Produktdokumente (Product Documents)

Purity:>99.50%Appearance:A solid

Chemische Eigenschaften (Chemical Properties)

CAS-Nr.
1134156-31-2
Synonyme
adenosine-derived inhibitor, VER155008, VER-155008
Chemischer Name
4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile
SMILES
C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N
Summenformel
C25H23Cl2N7O4
Molekulargewicht
556.4
Löslichkeit
≥ 27.8mg/mL in DMSO, ≥ 4.65 mg/mL in EtOH with ultrasonic and warming
Lagerung
Store at -20°C
Allgemeine Hinweise
Wählen Sie anhand der Löslichkeitsdaten des Produkts ein geeignetes Lösungsmittel. Aliquotieren Sie die Stammlösung nach der Herstellung, um wiederholte Gefrier-Auftau-Zyklen zu vermeiden.
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Versandbedingungen
Evaluierungsmuster werden mit Kühlakkus versandt. Andere verfügbare Größen werden bei Raumtemperatur oder auf Anfrage mit Kühlakkus versandt.

Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit

g/mol

Reviews

Review for VER 155008

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%